When it comes to our health, we will be most successful at advancing disease diagnostics if we can marry the benefits of genetic testing with protein testing, says Quanterix CEO and Executive Chairman, Kevin Hrusovsky. Click to read his article in Diagnostics World.
Resources by Therapeutic Area
Diagnostics World | September 2, 2016
Quanterix Opens Call for Proposals for Second Annual Accelerator Grant Program Focused on Oncology and Liquid Tumor Biopsy Technology
April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing.
This webinar describes a groundbreaking new technique published recently in Analytical Chemistry for measuring single cancer cells. The study, conducted by Dr. David Walt and his research group at Tufts University, demonstrates that the ultrasensitive Simoa technology makes it possible to quantify p…
March 7-9, 2016
Presentation: Leveraging Ultrasensitive Immunoassay Technology to Drive New Research and Clinical Insights to Immuno-Oncology
Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Journal of Urology | February 2016
In this study we evaluate an ultrasensitive prostate specific antigen assay in patients with prostate cancer after radical prostatectomy to predict long-term biochemical recurrence-free survival.